AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2

Chloe Philippe, Benoît Pinson, Jim Dompierre, Véronique Pantesco, Benoit Viollet, Bertrand Daignan-Fornier, Michel Moenner

To cite this version:
Chloe Philippe, Benoît Pinson, Jim Dompierre, Véronique Pantesco, Benoit Viollet, et al.. AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2. Neoplasia, 2018, 20 (6), pp.555-562. 10.1016/j.neo.2018.03.006 . hal-02346897

HAL Id: hal-02346897
https://hal.science/hal-02346897
Submitted on 5 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
AICAR Antiproliferative Properties Involve the AMPK-Independent Activation of the Tumor Suppressors LATS 1 and 2

Chloé Philippe*,†, Benoît Pinson*,†, Jim Dompierre*,†, Véronique Pantesco‡,§, Benoît Viollet‡,¶,#,**, Bertrand Daignan-Fornier*† and Michel Moenner*†

*Université de Bordeaux, IBGC UMR 5095, Bordeaux, France; †Centre National de la Recherche Scientifique, IBGC UMR 5095, Bordeaux, France; ‡CHU St Eloi, Montpellier, France; §Inserm U1040, Montpellier, France; ¶INSERM U1016, Institut Cochin, Paris, France; †CNRS (UMR 8104), Paris, France; #Université Paris Descartes, Sorbonne Paris Cité, Paris, France.

Abstract
AICAR (Acadesine) is a pharmacological precursor of purine nucleotide biosynthesis with anti-tumoral properties. Although recognized as an AMP mimetic activator of the protein kinase AMPK, the AICAR monophosphate derivative ZMP was also shown to mediate AMPK-independent effects. In order to unveil these AMPK-independent functions, we performed a transcriptomic analysis in AMPKα1/α2 double knockout murine embryonic cells. Kinetic analysis of the cellular response to AICAR revealed the up-regulation of the large tumor suppressor kinases (Lats) 1 and 2 transcripts, followed by the repression of numerous genes downstream of the transcriptional regulators Yap1 and Taz. This transcriptional signature, together with the observation of increased levels in phosphorylation of Lats1 and Yap1 proteins, suggested that the Hippo signaling pathway was activated by AICAR. This effect was observed in both fibroblasts and epithelial cells. Knockdown of Lats1/2 prevented the cytoplasmic delocalization of Yap1/Taz proteins in response to AICAR and conferred a higher resistance to the drug. These results indicate that activation of the most downstream steps of the Hippo cascade participates to the antiproliferative effects of AICAR.

Neoplasia (2018) 20, 555–562

Introduction
AICAR (5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside) is a pharmacologically active compound entering cells via purine transporters and being converted to its active-monophosphorylated form ZMP by adenosine kinase [1,2]. ZMP mimics AMP as a low-energy charge signal by activating the heterotrimeric AMP-activated protein kinase (AMPK), which promotes integrated regulatory functions at the cellular and tissular levels [3].

In mammal cells, an AICAR-induced cytotoxic response is observed, leading to both apoptotic and non-apoptotic death mechanisms [4–8]. Interestingly, AICAR is more cytotoxic for aneuploid cells compared to their euploid counterparts [6,9], which is of a great therapeutic interest since aneuploidy is observed in human in 90% of solid tumors and 85% of hematopoietic malignancies [10]. Moreover, AICAR showed antitumoral properties in vivo in different animal models [6,11,12] and is well tolerated in mice and human, even at elevated and repeated administration doses [13,14]. AICAR has been subjected to Phase I/II clinical trials for treating chronic lymphocytic leukemia [14].

Although AMPK activation has been initially recognized as a prevalent effect of AICAR, recent data indicated that many effects mediated by this compound are in fact AMPK-independent. These include inhibition of proliferation and limited tumor growth in vivo.

Abbreviations: AICAR, 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside; AMPK, adenosine monophosphate-activated protein kinase; CTGF, connective tissue growth factor (CCN2); CYR61, cysteine-rich angiogenic protein 61; HPRT, hypoxanthine-guanine phosphoribosyl transferase; LATS, large tumor suppressor kinase; MEFs, murine embryonic fibroblasts; Yap1, Yes-associated protein 1; TAZ, transcriptional coactivator with PDZ-binding motif; ZMP, AICAR monophosphate

Address all correspondence to: B. Daignan-Fornier, Université de Bordeaux, IBGC, 28610 La Teste de Buch, France. E-mail: b.daignan-fornier@ibgc.cnrs.fr or M. Moenner, Centre National de la Recherche Scientifique, IBGC UMR 5095, Bordeaux, France. E-mail: michel.moenner@u-bordeaux.fr

Received 30 January 2018; Revised 14 March 2018; Accepted 19 March 2018

© 2018. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1476-5586
https://doi.org/10.1016/j.neo.2018.03.006
[2,5,15–17]. These intriguing properties of AICAR therefore motivate the search for alternative targets of its metabolic derivative ZMP that could be exploited therapeutically.

In order to get further insight on the AMPK-independent action of AICAR, we carried out a kinetic analysis of the effects of AICAR on the transcriptome changes in murine embryonic fibroblasts (MEFs) invalidated for AMPK (α1 and α2 subunits) [18]. We identified Lats1 and Lats2 as early AICAR-induced genes and showed that the encoded proteins (herein referred as to Lats1/2) are potent mediators of the cell response to this drug. Lats1/2 proteins are downstream transducers of the core Hippo pathway known to play a pivotal role in the cell response to this drug. Lats1/2 proteins are downstream transducers of the core Hippo pathway known to play a pivotal role in cell cycle and density. These findings provide a rationale to analyze the effects of AICAR and motivate the research of derivatized compounds of AICAR with therapeutic perspectives.

**Materials and Methods**

**Reagents**

Culture media was from Invitrogen. Specific antibodies were as follows: Taz (#560235) (BD Pharmingen); actin (#A2668) (Sigma); AMPKα (#2532), PARP (#9542), LATS2 (#13646), LATS1 (#3477), phospho-(Thr1079)-LATS1 (#8654), LC3A/B (#4108), cleaved-(Asp175)-caspase-3 (#9604 and 9664), YAP1/TAZ (#8418), YAP1 (#14074 and #4912), phospho-(Ser127)-YAP1 (phospho-(-Ser112)-Yap1 in mice (#4911)) were from Cell Signaling; LATS2 (#NB200-199, NovusBio); DAPI and secondary antibodies labeled with AlexaFluor488 or with AlexaFluor555 were from ThermoFisher Scientific. Primers (Table S1) and siRNA (see below) were from Sigma. Control siRNA was from Cell Signaling (#6568). AICAR (#A611700, Toronto Research Chemicals, Canada) was solubilized in water and filtered at 0.22 μm. Its concentration was determined spectrophotometrically (A260; pH = 7; εmax = 12,700 M−1/cm−1).

**Cell Culture**

Human RPE-1 (ATCC; CRL-4000) cells were grown in DMEM, 4.5 g/L glucose supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. Wild-type and knock-out mouse embryonic fibroblasts (MEFs) for both AMPKα1 and AMPKα2 subunits (MEF-dKO) were obtained from the U1016-INSERM, Paris (Laderoute et al. [18]) and the absence of AMPKα in MEF-dKO was confirmed by Western blot (see text). The WST-1 cell viability assay was performed in 96-well plates as previously described [2]. Cell proliferation assays were performed in 24-well plates and cells were counted using a Multisizer 4 Coulter Counter (Beckman). Each time point was done in triplicate, and the averages ± STD were calculated. Experiments were repeated three times.

**Preparation of cRNA, Microarray Hybridization and Gene Expression Profiling**

Microarray analysis was performed at the Affymetrix transcriptome Platform, CHRU-Inserm U1040, Montpellier France (http://www.chu-montpellier.fr/fr/irmb/). MEF-dKO were grown in complete DMEM medium in the presence or absence of 1 mM AICAR and harvested at the indicated times (Final density -15,000 cells/cm²). Total RNA was extracted using the RNeasy kit (Qiagen, Santa Clarina, CA) and the quality of each sample was assessed on a Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Affymetrix Gene Chip 3’IVT Express Kit Bundle was used to generate amplified RNA. cRNAs were hybridized to Mouse MG-430 PM Array Strip Kit (44,000 probesets). All steps were performed according to the standard protocol of the manufacturer. Fluorescence intensities were quantified and analyzed using the Expression Console v 1.2 software. The converted digital intensity values were then converted into cell intensity files using the Affymetrix GeneAtlas Software. The fold change in gene expression corresponds to the ratio between each incubation times with AICAR and control without AICAR. Significance analysis of microarrays (SAM) analysis was applied in the different samples with 400 permutations, a fold change of 2 and a false discovery rate (FDR) < 3.55% (see Table S2A). All steps were conducted according to the MIAME (Minimum Information About a Microarray Experiment) checklist [21]. Annotation of genes was performed using NetAffx (http://www.affymetrix.com). Affymetrix IDs were submitted to the DAVID analysis tool (http://david.abcc.ncifcrf.gov/home.jsp), the NetAffx Analysis Center (https://www.affymetrix.com/analysis/com pare/index.affx) and the KEGG pathway database (www.genome.jp/kegg/pathway.html) to depict biological processes associated with the functions of regulated genes. Data files were deposited in the Gene Expression Omnibus (GEO) database (accession number, GSE106460; www.ncbi.nlm.nih.gov/geo).

**Small Interfering RNA Knockdown**

Cells were plated at a density of 5.10⁴ cells per well in six-well plates. Small interfering RNA (siRNA) against human and mouse LATS1 (sihmLATS1): CACGCGAAGAUAGGAAUU; human and mouse LATS2 (sihmLATS2-y): GAAGAUGUAUUUUGUAUUAA; mouse AMPKα1/2_human AMPKα2 (simAMPKα1/2 sihAMPKα2): GAGAAGCGAAGGAGCACGC, human AMPKα1 (sihAMPKα1): AUGUAUUAAUUGAAGAAGCCA were from Sigma. Non-targeting siRNA (#D-001810-01-20) was from Dharmaco (Lafayette, CO). Transfection was performed for 6–15 h using lipofectamine RNAiMax (Invitrogen) according to the manufacturer’s protocol, with total amounts of siRNA at a final concentration of 10–60 nM, as indicated in the figure legends.

**Immunoblot**

Cells in culture dishes were collected using a rubber policeman and snap frozen. Proteins were extracted at 4°C with RIPA buffer containing phosphatase inhibitors (PhosStop EasyPack, ROCHE) and protease inhibitors (Complete ULTRA Tablets, mini EasyPack, ROCHE). Protein content was determined by using a BCA protein assay kit (Pierce). Proteins were resolved on 7 or 10% SDS-PAGE, transferred to a PVDF blotting membrane (Hybond P 0.45 μm PVDF membrane; Amersham) and probed using primary antibodies. Secondary antibodies coupled to HRP were used for revelation. Densitometric analyses were carried out using ImageJ (http://rsbweb.nih.gov/ij/download.html) and results were normalized to the actin loading control.

**Real-Time PCR**

Cells in culture dishes were solubilized in Trizol (Life Technologies) and frozen at -80°C until use. RNA extraction, quantification and gene expression analyses by RT-qPCR were performed as
previously reported [22]. Gene expression was normalized to actin and HPRT1. Results were the mean of triplicate determinations ± SD.

**Immunofluorescence**
MEFs and RPE-1 cells were seeded at the density of 7,000 cells/cm² on 18-mm glass coverslips N° 1.5H (Marienfeld, Germany). After one day of incubation, cells were washed and incubated with AICAR for the indicated times. They were then washed with PBS, fixed for 20 min with 4% paraformaldehyde in PHEM, permeabilized with 0.1% Triton X-100 in PBS and blocked in 0.1% BSA in PBS for 15 min. Cells were then incubated first for 60 min at 37°C in the blocking buffer containing anti-Yap1 or anti-Taz antibodies, followed by incubation with AlexaFluor 488-labeled anti-rabbit antibodies (Yap1) or AlexaFluor 555-labeled anti-mouse antibodies (Taz). Nuclei were counter-stained with DAPI. Microphotographs were obtained using an Olympus IX81 inverted microscope (Olympus, Rungis, France) with a 40x oil immersion objective, NA 1.3. Image analyses were carried out using ImageJ free software. Statistical analyses were based on the quantification of the fluorescent signal on at least 10 different fields (>50 cells per condition).

**Results**

**AMPK-Independent Transcriptional Response to AICAR in MEF-dKO**
In order to get a dynamic view of the transcriptomic response to AICAR, a 24-h kinetic analysis was carried out in MEF-dKO AMPK in the presence of 1 mM AICAR, a condition resulting in robust ZMP accumulation in both MEF-dKO and MEF-wt (Figure S1). We observed that the absence of AMPK did not significantly affect the propagation of MEFs in standard culture conditions (Figure S2A). However, the MEF-dKO were slightly more sensitive than MEF-wt to the highest dose of the drug, as monitored by using a cytotoxic assay (Figure S2, B and C) and analyses of the apoptotic process using standard procedures (Figure S2, D and E). By assessing the transcriptome across seven time points in MEF-dKO (Figure 1A), significance analysis of microarray (SAM) revealed that 1325 probesets (1071 genes; 19.1% redundancy), corresponding to ~2.9% of the total number of the probesets available on the chips, were AICAR-responsive (minimum 2-fold change; FDR (%) < 3.55, values given in Table S2A). The number of genes modulated under AICAR treatment increased with time (Figure 1B). A majority of genes were down regulated at early times (100% at t = 1 h), while a similar number of genes were up- and down- regulated from 8 to 24 h of incubation. The variation of gene expression pattern indicated that 627 AICAR-responsive probesets (47.3%) were consistently up-regulated overtime whereas 697 probesets (52.6%) were strictly down-regulated (Table S2A).

An early and sustained up-regulation of transcripts encoding the large tumor suppressor proteins Lats1 and Lats2 was detected along the time-course experiment (Figure 1C). Lats1/2 are protein kinases and members of the Hippo pathway core, which is critically involved in mammals in several processes including growth inhibition, survival, epithelial to mesenchymal transition and the response to stressors. A major Hippo signaling outcome is the inhibition by Lats1/2 of the two highly related oncoproteins Yap1 (Yes-associated protein 1) and Taz (transcriptional co-activator with PDZ-binding motif) [19,20]. We therefore questioned the possible impact of AICAR on the transcriptional activities of Yap1 and Taz. Comparison of transcriptome signatures in human cells overexpressing YAP1 or TAZ [23] with transcripts responding to AICAR revealed an overlap of ~200 genes. Notably, most of these genes were detected lately (12 and 24 h) upon AICAR treatment, well after the onset of Lats1/2 up-regulation (Figure 1C). Several of these genes, including CcnD1, Ctgf, Cyr61, Iris1 and Thbs1 (Figure C and Table S2A) are well-recognized Hippo targets [24–26]. Further combination of literature and data mining established an expandable common gene signature of AICAR and Yap1/Taz, currently representing ~19% of the total number of genes regulated by AICAR (Table S2B). The extent of this overlap is likely underestimated here, since comparisons were carried out between mice (AICAR signature) and human (YAP1/TAZ signatures), the gene symbol attribution being somewhat different in the two organisms. The GO-term enrichment profile of AICAR-responsive genes predominantly points to the regulation of gene expression, nucleotide binding and mRNA processing (Table S3). Of note, AICAR treatment could also have concurrent effects on cell proliferation by the coordinate inhibition of several genes functionally linked to the epidermal growth factor (EGF) and to the insulin/insulin-like growth factor (IGF) signaling pathways (Table S4). Repression of several of these genes is expected to contribute to the inhibition of Yap1/Taz functions [27,28]. Most of these events occurred later in time and are likely subordinated to primary events triggered by AICAR. Overall, analysis of the gene-expression profile pointed to the Hippo signaling pathway as a major target of AICAR in MEF-dKO (Figure 1D).

**The Hippo Pathway is Activated Under AICAR Treatment**
RT-PCR analysis validated the fact that Lats1 and Lats2 mRNAs were increased in MEF-dKO in response to AICAR (Figure 2A). These effects were associated to the progressive decrease in the level of both Cyr61 and Ctgf transcripts, two surrogate markers of Hippo pathway activation and Yap1/Taz inhibition. Importantly, these effects were found whether AMPK was present or not, i.e. in both MEF-dKO and MEF-wt (Figure 2A).

Lats1/2 protein levels were also increased after 4 h of incubation in the two isogenic cell lines as measured by Western blot (Figure 2, Ba and Ca). Activation of the Hippo pathway under AICAR treatment was further confirmed by the increased phosphorylation of the proteins Lats1/2 using an antibody directed against phospho-(Thr1079)-LATS1 that also partially cross-reacts with p-LATS2 (Figure 2, Ba and Ca). Phosphorylation of Lats1/2 was accompanied in both cell lines by the increase of Yap1 phosphorylation (p-S112-Yap1) (Figure 2, Bb and Cb), a marker of Yap1 inhibition by Lats1/2 [19,20]. The total amounts of Yap1 and Taz proteins were also increased under AICAR treatment, in agreement with results obtained by others in HepG2 cells [29]. Thus, Lats1/2 were up-regulated at both the mRNA and protein levels upon AICAR treatment, and this effect was associated with their activating phosphorylation. These events did not require the presence of AMPK, as they were observed in both MEF-dKO and MEF-wt cells.

**AICAR Treatment Promoted Nuclear Delocalization of YAP1/TAZ**
One reported consequence of the activation of the Hippo pathway is the nuclear exclusion of YAP1/TAZ [19,20]. Hence, we performed immunofluorescence analyses on MEF-wt and MEF-dKO subjected or not to AICAR treatment. As shown in Figure S3, A-B, both Yap1 and Taz immunoreactivities were predominantly nuclear in control conditions. Besides, a modest but reproducible delocalization of the signal (<50%) was measured in these cells at different incubation times with AICAR. We considered that this limited nuclear exclusion...
of Yap1/Taz in MEFs could be the consequence of the cellular immortalization by SV40 large T antigen [18], the Hippo pathway being perverted by viral oncoproteins [30,31]. We therefore designed a control experiment based on the well-described subcellular delocalization of YAP1 in cell–cell contact condition at high cell density [26]. Strikingly, endogenous signals associated to a high cell density did not lead either to a substantial delocalization of Yap1 in immortalized MEFs, whereas a robust translocation was observed in human retinal epithelial (RPE-1) cells (Figure S3C). In keeping with this, we observed that primary cultured MEF readily responded to AICAR treatment by the unambiguous decrease of both Yap1 and Taz immunoreactivities in the nuclear compartment (Figure S3D). Thus, subcellular delocalization of Yap1/Taz under AICAR treatment was readily observed in primary cultured MEFs and was attenuated in SV40-immortalized MEFs. Noticably, inhibition of Yap1 in immortalized MEFs was dissociated from its complete cytoplasmic translocation.

The effect of AICAR on the Hippo pathway was indeed confirmed in RPE-1 cells. AICAR induced a time-dependent redistribution of YAP1 and TAZ from the nucleus to the cytoplasm (Figure 3A and B) due to a rapid (t < 4 h) decrease of the corresponding signals in the nucleus. This effect was followed by their late (t > 8 h) extinction in the cytosol (Figure 3B). A higher expression of LATS1 protein was consistently observed after 4 h of treatment (Figure S4A). Overall, these results indicated that AICAR regulates YAP1/TAZ subcellular localization in polarized epithelial cells as well as in fibroblasts.
Finally, we analyzed the implication of LATS1/2 in the AICAR-mediated translocation of YAP1 by siRNA LATS1/2 knockdown approaches, which efficiently reduced the expression of the corresponding proteins in RPE-1 cells (Figure S4B). In cells treated with the non-targeting siRNA, AICAR treatment induced the cytoplasmic delocalization and decrease of the YAP1 protein (Figure 3, C and D). In comparison, delocalization of YAP1 was abolished when RPE-1 cells were treated with siRNA targeting LATS1/2 mRNA. We concluded that the decrease of the nuclear fraction of YAP1 under AICAR treatment was dependent on LATS1/2.

Knockdown of LATS1/2 Rescued Proliferation of Human and Mice Cells Under AICAR Treatment

LATS1/2 being essential for the YAP1/TAZ-mediated effects of AICAR, we then used the knockdown approach to evaluate the impact of LATS1/2 activation on AICAR-mediated cytotoxicity. Cellular viability was measured in MEF-wt and RPE-1 cells treated or not with AICAR, siRNA knockdown against LATS1/2 induced a strong decrease of the level of the corresponding proteins in these cells (Figure S4, B and C) and significantly restored their growth in the presence of AICAR (Figure 4). The higher resistance of MEF and RPE-1 cells to AICAR treatment is consistent with the expected effect of LATS1/2, these protein kinases acting as potent repressors of proliferation through phosphorylation/inhibition of Yap1/Taz activities was detected in both cell types.

**Figure 2.** AMPK-independent activation of the Hippo pathway under AICAR treatment. RT-qPCR and Western blot analyses of MEF-wt and MEF-dKO. Exponentially growing cells were stimulated or not with AICAR for different times and cell extracts were subjected to RT-qPCR or to Western blot analyses. Specific antibodies of the following proteins and phosphorylations were used: Lats1, Lats2, phospho-(Thr1079)-Lats1/2, Yap1, phospho-(Ser127)-Yap. A) RT-qPCR analyses: early induction (t = 4 h) of Lats1/2 transcripts and late transcripts repression of the reporter genes Cyr61 and Ctgf in MEF-wt and MEF-dKO. Dotted lines represent control values in the absence of AICAR. (*P < .05; **P < .01; ***P < .001). (B-C) Western blot: Lats1/2 were phosphorylated in MEF-dKO (B) and in MEF-wt (C) in response to AICAR. Lats1 and Lats2 proteins were induced following treatment with AICAR and phosphorylation/inhibition of Yap1/Taz activities was detected in both cell types.

**Discussion**

AICAR is a purine precursor endowed with therapeutic properties [32]. Its intracellular monophosphorylated form (ZMP) mimics the binding of AMP to the low energy sensor regulatory enzyme AMPK, and is therefore widely used as an energy-stress mimicking agonist [3,33]. Recent studies also pointed to AICAR as a potent modulator of AMPK-independent functions in mammals. Such effects converge towards cell growth inhibition and cytotoxicity [2,5,15,16].
Interestingly, a higher sensitivity of aneuploid cells versus euploid cells to AICAR treatment was evidenced in different cell models, offering appealing perspectives in cancer therapy [6,9].

By using an unbiased approach, we aimed at identifying cellular functions that could be modulated by AICAR independently of AMPK. We carried out a gene expression microarrays analysis using...
the AMPKα1/α2 double knockout MEF model. Time-course analysis indicated that these cells responded to AICAR treatment by up-regulating the tumor suppressor genes Lats1 and Lats2, both of which encode the most downstream protein kinases of the Hippo cascade. This effect, hereby defined as to the early cell response (~2–4 h) to AICAR, was accompanied with the increase in the corresponding proteins Lats1/2. Phosphorylation of Lats1 was also observed on its threonine residue 1079, a molecular marker of its catalytic activation. In a late (≥ 12 h) cell response to AICAR, down-regulation of a collection of gene was displayed as a signature of the repression of Yap1/Taz transcriptional coactivators. These finding were in good agreement with the fact that AICAR promoted Yap1/ Taz inhibitory phosphorylation as well as their subcellular delocalization. One prominent response of mammalian cells to AICAR is therefore the downstream activation of the Hippo signaling cascade, leading to the blockade of Yap1/Taz effector functions. Remarkably, knockdown of Lats1/2 partially rescued the growth of AICAR-treated cells, which established that Lats1/2 activity is indeed involved in the antiproliferative effect of this drug.

Lats1/2 play a central role in tissue growth and size in metazoans [20,26]. In addition, Lats1/2 (acting as tumor suppressors) and Yap1/ Taz (as proto-oncogenes) are involved at critical stages of tumor progression [34–38]. Thus, it may come as no surprise that AICAR interferes with mechanisms linked to the cell cycle, inhibition of proliferation, decrease of cell migration/invasion, inhibition of the epithelial–mesenchymal transition (EMT) and induction of apoptosis (see for example [2,4,5,39,40]). In xenograft models, AICAR consistently slows tumor progression, inhibits tumor cell invasion and also expresses anti-angiogenic properties [12,41].

The cellular response to AICAR was observed in MEF-dKO cells and thus did not require the presence of AMPK. Notably, AICAR activation in the absence of AMPK did not exactly replicate in MEF-wt, suggesting that the AMPK pathway could also modulate LATS and YAP1 activities. Indeed, AMPK was previously shown to inhibit YAP1 by direct phosphorylation, and was also able to activate LATS [29,42]. In addition, AICAR-activated AMPK signaling repressed the transcription of YAP1-regulated genes CTGF and CYR61 in LATS1/2 double knockdown cells [29,42]. Two parallel pathways, involving either AMPK or LATS kinases, may therefore converge to YAP1 inhibition under AICAR treatment. The rapid post-translational activation (in minutes) of AMPK upon AICAR binding has however to be distinguished from the transcriptional activation of LATS1/2 (≥ 2 h) reported here. Interestingly, YAP1 activity is inhibited by both AMPKα1/α2 kinases and LATS1/2 kinases through phosphorylation at distinct sites (YAP-Ser61/Ser94 and YAP-Ser127, respectively) [29,42], which suggests complementary downstream functions of AICAR through these two types of regulatory kinases. Inhibition of YAP1-dependent transcription using paired signals (i.e. AMPK- and LATS-dependent) may conform physiologically with the energetic and biosynthetic status of the cells as well as with the mechanical constraints imposed by their positioning in tissues [20,43].

These findings broaden our knowledge of AICAR’s antitumor properties. They provide a rationale for the development of derivatized pharmacological compounds by exploiting the antitumor properties of the Hippo pathway through activation of LATS1/2. Caution must be taken however when considering such approaches. Besides the most characteristic YAP1/TAZ targets, other LATS1/2 kinases substrates were identified, including AMOT, AF6, PARD3A and NUMA1 proteins whose functions are involved in the organization of the actin network or in the mitotic spindle orientation [38]. These, as well as other YAP1/TAZ-independent effects of LATS [44], arguably enlarge the contribution of AICAR as a multi-target drug for different tumor types. Besides its opposing effect on tumor progression through AMPK activation [29,45], an awaited effect of AICAR, or of derivatized analogs, in therapy would be its ability to reactivate LATS1/2 in tissues presenting altered upstream signals in a variety of diseases [34–38].

In conclusion, a transcriptomic approach established that the Hippo pathway was stimulated under AICAR treatment even in the absence of AMPK. AICAR activated the tumor suppressors LATS1/2 and, consequently, inhibited the co-transcriptional activators YAP1/ TAZ and downstream-regulated genes in an AMPK-independent manner. Functionally, the inhibition of cell proliferation by AICAR was due, in part, to the presence of LATS1/2.

Supplementary data to this article can be found online at https://doi.org/10.1016/j.neo.2018.03.006.

Disclosure of potential conflicts of interest
The authors declare no conflict of interests.

Acknowledgements
This work was supported by Ministère de l’Éducation Nationale de l’Enseignement Supérieur et de la Recherche (C. P.), Centre National de la Recherche Scientifique, and by grants from the Ligue Nationale Contre le Cancer, Comité des Landes (L.A.R.G.E project, M.M.), Comité de la Gironde (M. M.); Association pour la Recherche sur le Cancer (ARC SFI 201221205915, B. D-F.).

References
[1] Sabina RL, Patterson D, and Holmes EW (1985). 5-Amino-4-imidazolecarboxamide riboside (Z-riboside) metabolism in eukaryotic cells. J Biol Chem 260, 6107–6114.
[2] Ceschin J, Saint-Marc C, Laforture J, Labriet A, Philippe C, Moenner M, Daignan-Fornier B, and Pinson B (2014). Identification of yeast and human 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside (AICAR) transporters. J Biol Chem 289, 16844–16854.
[3] Hardie DG (2014). AMPK— sensing energy while talking to other signaling pathways. Cell Metab 20, 939–952.
[4] Gonzalez-Girones DM, Moncunill-Massagué C, Iglesias-Serret D, Cosiálls AM, Perez-Perarnau A, Palmeri CM, Rubio-Patino C, Villunger A, Pons G, and Gil J (2013). AICAR induces Bas/Bak-dependent apoptosis through upregulation of the BH3-only proteins Bim and Noxa in mouse embryonic fibroblasts. Apoptosis. 18, 1008–1016.
[5] Santridjan AF, Gonzalez-Girones DM, Iglesias-Serret D, Coll-Mulet L, Cosiálls AM, de Frías M, Campos C, Gonzalez-Barca E, Alonso E, Labi V, et al (2010). AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Blood 116, 3023–3032.
[6] Tang YC, Williams BR, Siegel JJ, and Amon A (2011). Identification of aneuploidy-selective antiproliferation compounds. Cell 144, 499–512.
[7] Bardeleben C, Sharma S, Reeve JR, Basillian S, Frost P, Hoang B, Shi Y, and Lichtenstein A (2013). Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminimidazole-4-carboxamide-1-beta-ribofuranoside-induced apoptosis in multiple myeloma cells. Mol Cancer Ther 12, 1310–1321.
[8] Robert G, Ben Sahra I, Puissant A, Colosetti P, Belhacene N, Gounon P, Hofman P, Bout F, Cassuto JP, and Aubeger P (2009). Academe kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death. PLoS One 4e7889.
[9] Ly P, Kim SB, Kaisani AA, Martin G, Wright WE, and Shay JW (2013). Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation. Oncogene 32, 3139–3146.
Cebola I, Rodriguez-Segui SA, Cho CH-H, Bessa J, Rovira M, Luengo M, Zhang H, Liu CY, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, and Guan KL (2016). Mechanisms of Hippo pathway regulation. *Genes Dev* 30, 1–17.

Sudol M (2014). Neuregulin 1-activated ERBB4 as a "dedicated" receptor for the Hippo-YAP pathway. *Sci Signal* 7, pe29.

Strasserbrug K, Tiebe M, Pintsa F, Breuhahn K, and Telemman AA (2012). Insulin/IGF signaling drives cell proliferation in part via Yorkie/YAP. *Dev Biol* 367, 187–196.

Mo JS, Meng Z, Kim VC, Park HW, Hansen CG, Kim S, Lim DS, and Guan KL (2015). Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. *Nat Cell Biol* 17, 500–510.

Nguyen HT, Hong X, Tan S, Chen Q, Chan L, Fivaz M, Cohen SM, and Voorhoeve PM (2014). Viral small T oncoproteins transform cells by alleviating hippo-pathway-mediated inhibition of the YAP proto-oncogene. *Cell Rep* 8, 707–713.

Shanzer M, Ricardo-Lax I, Keshet R, Reuvven N, and Shaull Y (2015). The polyomavirus middle T-antigen oncopage activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner. *Oncogene* 34, 4190–4198.

Daigian-Fornier B and Pinson B (2012). 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranosyl (AICAR), a Highly Conserved Purine agonists are exercise mimetics.

Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Hansen CG, Moroishi T, and Guan KL (2009). YAP and TAZ: a nexus for growth and epithelial-mesenchymal transition. *Nat Cell Biol* 626.

Day P, Sharff A, Parra L, Cleasby A, Williams M, Horer S, Nar H, Redemann N, Tickle I, and Yong J (2007). Structure of a CBS-domain pair from the regulatory gamma1 subunit of human AMPK in complex with AMP and ZMP. *Acta Crystallogr D Biol Crystallogr* 63, 587–596.

Visser S and Yang X (2010). LATS tumor suppressor: a new governor of cellular homeostasis. *Cell Cycle* 9, 3892–3903.

Zanconato F, Cordenonsi M, and Piccolu S (2016). YAP/TAZ at the Roots of Cancer. *Cancer Cell* 29, 783–803.

Harvey KF, Zhang X, and Thomas DM (2013). The Hippo pathway and human cancer. *Nat Rev Cancer* 13, 246–257.

Moroishi T, Hansen CG, and Guan KL (2015). The emerging roles of YAP and TAZ in cancer. *Nat Rev Cancer* 15, 73–79.

Pfleger CM (2017). The Hippo Pathway: A Master Regulatory Network Important in Development and Dysregulated in Disease. *Curr Top Dev Biol* 123, 181–228.

Sheng B and Canley LC (2007). Regulation of epithelial right junction assembly and disassembly by AMP-activated protein kinase. *PNAS* 104, 819–822.

Chou CC, Lee KH, Lai HL, Wang D, Mo X, Kulp SK, Shapiro CL, and Chen CS (2014). AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. *Cancer Res* 74, 4793–4795.

Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, and Lim JS (2012). Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. *Biochem Pharmacol* 83, 385–394.

Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL, and Chen J (2015). AMPK modulates Hippo pathway activity to regulate energy homeostasis. *Nat Cell Biol* 17, 490–499.

Santinon G, Pocaterra A, and Dupont S (2016). Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. *Trends Cell Biol* 26, 289–299.

Britschgi A, Duss S, Kim S, Zou JP, Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, et al (2017). The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERAlpha. *Nature* 541, 541–545.

Li W, Saud SM, Young MR, Chen G, Hua B, and Targeting AMPK (2015). for cancer prevention and treatment. *Onco Targets* 6, 7369–7378.